NautaDutilh acted as Belgian and Dutch underwriters' counsel, alongside Cooley LLP. Among others, the underwriters consisted of Morgan Stanley, BofA Securities and Cowen.
Two days before launch of the offering on February 1, argenx announced its plan to continue enrolment in the trial evaluating its medicine efgartigimod for the treatment of the chronic disease CIDP. This resulted in a share price increase of the ADSs on Nasdaq of 11% to USD 324.62 USD and of the shares on Euronext Brussels of 10% to EUR 265.59.
The deal team consisted of Petra Zijp, Sabrina Legerstee and Charlotte Sonneveld for Dutch law and Nicolas de Crombrugghe, Lentle and Alexandra Watrice for Belgian law.